$34.47
8.98% today
Nasdaq, Apr 01, 06:50 pm CET
ISIN
US74006W1080
Symbol
PRAX
Sector
Industry

Praxis Precision Medicines Inc Stock price

$37.87
-0.73 1.89% 1M
-19.67 34.18% 6M
-39.09 50.79% YTD
-20.73 35.38% 1Y
-115.28 75.27% 3Y
-247.13 86.71% 5Y
-247.13 86.71% 10Y
Nasdaq, Closing price Mon, Mar 31 2025
-0.79 2.04%
ISIN
US74006W1080
Symbol
PRAX
Sector
Industry

Key metrics

Market capitalization $763.58m
Enterprise Value $372.38m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 43.55
P/S ratio (TTM) P/S ratio 89.31
P/B ratio (TTM) P/B ratio 1.65
Revenue growth (TTM) Revenue growth 249.53%
Revenue (TTM) Revenue $8.55m
EBIT (operating result TTM) EBIT $-200.17m
Free Cash Flow (TTM) Free Cash Flow $-131.76m
Cash position $392.57m
EPS (TTM) EPS $-10.27
P/E forward negative
P/S forward 519.44
EV/Sales forward 253.32
Short interest 10.23%
Show more

Is Praxis Precision Medicines Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Praxis Precision Medicines Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Praxis Precision Medicines Inc forecast:

10x Buy
91%
1x Sell
9%

Analyst Opinions

11 Analysts have issued a Praxis Precision Medicines Inc forecast:

Buy
91%
Sell
9%

Financial data from Praxis Precision Medicines Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
8.55 8.55
249% 249%
100%
- Direct Costs 0.36 0.36
66% 66%
4%
8.20 8.20
486% 486%
96%
- Selling and Administrative Expenses 56 56
39% 39%
650%
- Research and Development Expense 152 152
76% 76%
1,783%
-200 -200
59% 59%
-2,337%
- Depreciation and Amortization 0.36 0.36
66% 66%
4%
EBIT (Operating Income) EBIT -200 -200
58% 58%
-2,341%
Net Profit -183 -183
48% 48%
-2,138%

In millions USD.

Don't miss a Thing! We will send you all news about Praxis Precision Medicines Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Praxis Precision Medicines Inc Stock News

Neutral
GlobeNewsWire
28 days ago
BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on March 3, 2025, the Compensation Committee of Praxis' Board of Directors g...
Positive
Seeking Alpha
29 days ago
Ulixacaltamide's Phase 3 study was recommended to stop for futility, significantly lowering its chances of success in essential tremor. Investor focus shifts to the epilepsy pipeline, led by vormatrigine (focal epilepsy) and relutrigine (SCN2A/SCN8A-DEEs). Vormatrigine must differentiate from Xcopri and XEN1101 in a highly competitive focal epilepsy market.
Neutral
GlobeNewsWire
about one month ago
BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided an update on the interim analysis for Study 1 of the Essential3 program of ulixacal...
More Praxis Precision Medicines Inc News

Company Profile

Praxis Precision Medicines, Inc. is a clinical-stage genetic neuroscience company that develops therapies for patients and families affected by complex and debilitating brain disorders. The company was founded by Kiran Reddy, David Goldstein and Steven Petrou on September 22, 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Marcio Souza
Employees 116
Founded 2015
Website www.praxismedicines.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today